[go: up one dir, main page]

AR035312A1 - HYDROXAMIC ACID COMPOUNDS CONTAINING ALQUINYL AS MATRIX / TACE METALOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITION THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT - Google Patents

HYDROXAMIC ACID COMPOUNDS CONTAINING ALQUINYL AS MATRIX / TACE METALOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITION THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Info

Publication number
AR035312A1
AR035312A1 ARP000100327A ARP000100327A AR035312A1 AR 035312 A1 AR035312 A1 AR 035312A1 AR P000100327 A ARP000100327 A AR P000100327A AR P000100327 A ARP000100327 A AR P000100327A AR 035312 A1 AR035312 A1 AR 035312A1
Authority
AR
Argentina
Prior art keywords
heteroaryl
aryl
alkyl
cycloalkyl
acid compounds
Prior art date
Application number
ARP000100327A
Other languages
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR035312A1 publication Critical patent/AR035312A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de ácido hidroxámico que contienen alquinilo caracterizados porque comprenden un compuesto que tiene la fórmula (1) en la cual R1 es hidrogeno, arilo, heteroarilo, alquilo de C1-8, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-6, o cicloheteralquilo de C4-8; R2 y R3 son cada uno independientemente hidrógeno, alquilo de C1-6, -CN, o -CCH; R7 es hidrógeno, arilo, aralquilo, heteroarilo, heteroaralquilo, alquilo de C1-6, alquenilo de C2-6, alquinilo de C1-6, cicloalquilo de C3-6, -C(O)-R1, -SO2-R1, -C(O)-NHR1, -C(O)NR5R6, -C(O)R1NR5R6, -C(O)-OR1, -C(NH)-NH2, R8, R9, R10 y R11 son cada uno independientemente, hidrógeno, arilo o heteroarilo, cicloalquilo de C3-6, cicloheteroalquilo C4-8, alquilo de C1-18, alquenilo de C2-18, alquinilo de C2-18, con la condición de que uno de los pares R8, R9, R9 y R10 o R10 y R11 conjuntamente con el átomo o átomos de carbono a los cuales están unidos forman un anillo cicloalquilo de C3-6, o un anillo cicloheteroarilquilo C4-8; R12 es hidrógeno, arilo o heteroarilo, cicloalquilo de C3-6, cicloheteroalquilo C4-8, o alquilo de C1-6; A es O, S, SO, SO2, NR7 o CH2; X es O, S, SO, SO2, NR7 o CH2; Y es arilo o heteroarilo, con la condición de que A y X no están unidos a los átomos adyacentes de Y; y n es 0-2; o una sal farmacéuticamente aceptable del mismo.Alkynyl-containing hydroxamic acid compounds characterized in that they comprise a compound having the formula (1) in which R 1 is hydrogen, aryl, heteroaryl, C 1-8 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl of C3-6, or C4-8 cycloheteralkyl; R2 and R3 are each independently hydrogen, C1-6 alkyl, -CN, or -CCH; R7 is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, C1-6 alkyl, C2-6 alkenyl, C1-6 alkynyl, C3-6 cycloalkyl, -C (O) -R1, -SO2-R1, - C (O) -NHR1, -C (O) NR5R6, -C (O) R1NR5R6, -C (O) -OR1, -C (NH) -NH2, R8, R9, R10 and R11 are each independently, hydrogen , aryl or heteroaryl, C3-6 cycloalkyl, C4-8 cycloheteroalkyl, C1-18 alkyl, C2-18 alkenyl, C2-18 alkynyl, provided that one of the pairs R8, R9, R9 and R10 or R10 and R11 together with the carbon atom or atoms to which they are attached form a C3-6 cycloalkyl ring, or a C4-8 cycloheteroaryl ring; R12 is hydrogen, aryl or heteroaryl, C3-6 cycloalkyl, C4-8 cycloheteroalkyl, or C1-6 alkyl; A is O, S, SO, SO2, NR7 or CH2; X is O, S, SO, SO2, NR7 or CH2; Y is aryl or heteroaryl, with the proviso that A and X are not attached to the adjacent atoms of Y; and n is 0-2; or a pharmaceutically acceptable salt thereof.

ARP000100327A 1999-01-27 2000-01-26 HYDROXAMIC ACID COMPOUNDS CONTAINING ALQUINYL AS MATRIX / TACE METALOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITION THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AR035312A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23803899A 1999-01-27 1999-01-27

Publications (1)

Publication Number Publication Date
AR035312A1 true AR035312A1 (en) 2004-05-12

Family

ID=22896246

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100327A AR035312A1 (en) 1999-01-27 2000-01-26 HYDROXAMIC ACID COMPOUNDS CONTAINING ALQUINYL AS MATRIX / TACE METALOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITION THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Country Status (13)

Country Link
JP (1) JP2002535390A (en)
KR (1) KR20010101732A (en)
AR (1) AR035312A1 (en)
AT (1) ATE309986T1 (en)
AU (1) AU769418B2 (en)
CA (1) CA2356313A1 (en)
CZ (1) CZ20012711A3 (en)
DE (1) DE60024056D1 (en)
EA (1) EA200100806A1 (en)
HU (1) HUP0200223A3 (en)
IL (1) IL144345A0 (en)
NZ (1) NZ512566A (en)
ZA (1) ZA200105222B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058350A1 (en) * 2002-12-26 2006-03-16 Carna Biosciences, Inc. Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient
AU2007269836A1 (en) * 2006-06-30 2008-01-10 Albany Molecular Research, Inc. Substituted piperidines that increase P53 activity and the uses thereof
KR20110022635A (en) * 2008-06-02 2011-03-07 시플라 리미티드 Synthesis of Levocetirizine and Intermediates for Use therein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000075808A (en) * 1997-02-27 2000-12-26 윌리암 에이취 캘넌, 에곤 이 버그 N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
NZ506184A (en) * 1998-02-19 2003-05-30 American Cyanamid Co N-hydroxy-2-(alkyl, aryl, or heteroaryl sulphanyl, sulphinyl or sulphonyl)-3-substituted-alkyl, aryl or heteroarylamides useful as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
HUP0200223A2 (en) 2002-06-29
EA200100806A1 (en) 2002-08-29
AU769418B2 (en) 2004-01-29
ATE309986T1 (en) 2005-12-15
CA2356313A1 (en) 2000-08-03
IL144345A0 (en) 2002-05-23
NZ512566A (en) 2004-02-27
AU2630500A (en) 2000-08-18
KR20010101732A (en) 2001-11-14
HUP0200223A3 (en) 2002-12-28
DE60024056D1 (en) 2005-12-22
ZA200105222B (en) 2002-09-25
CZ20012711A3 (en) 2002-05-15
JP2002535390A (en) 2002-10-22

Similar Documents

Publication Publication Date Title
AR035313A1 (en) ACETILENIC TACE INHIBITORS OF HYDROXAMIC ACID OF SULFONAMIDE BASED ON ALFA-AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES.
ECSP22012347A (en) SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS
PE20230238A1 (en) KRAS G12C INHIBITORS
AR011093A1 (en) COMPOUNDS DERIVED FROM SULFONIL UREA, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND PROCEDURE FOR ITS USE.
AR082152A1 (en) DERIVATIVES OF N- (METILSULFONIL) BENZAMIDE, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF NAV1.7
AR035311A1 (en) HYDROXAMIC ACID DERIVATIVES CONTAINING ALQUINYL, AS INHIBITORS OF THE METALLOPROTEINAS OF MATRIX AND THE TACE, PHARMACEUTICAL COMPOSITION AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR038235A1 (en) N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEIVER
PE20250021A1 (en) CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS
PE20040949A1 (en) DERIVATIVES OF HEXAHIDRO-PIRAZINO [1,2-a] PIRIMIDIN-4,7-DIONA SUBSTITUTED IN POSITION 3 BY NITROGEN AND PROCEDURE FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITION
AR084768A1 (en) MODULATORS OF THE COMPLEMENT PATH AND USES OF THE SAME
ATE186548T1 (en) NEW AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
AR053120A1 (en) AMINOPIRIDINS AS INHIBITORS OF BETA SECRETASA
AR083849A1 (en) ESPIRO-OXINDOL MDM2 ANTAGONISTS
AR058073A1 (en) IMIDAZOL 5-IL-PYRIMIDINE DERIVATIVES, OBTAINING PROCESSES, PHARMACEUTICAL COMPOSITIONS AND USES
AR050261A2 (en) AMINO ACIDS AFFECTED BY THE ALFA-2-DELTA PROTEIN AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE TO PREPARE A MEDICINAL PRODUCT
CO5690588A2 (en) DERIVATIVES OF 4-TETRAZOLILO-4 PHENYLPIPERIDINE FOR PAIN TREATMENT
AR040048A1 (en) DERIVATIVES OF 1- (AMINOALQUIL) -3-SULFONYLINDOL AND INDAZOL AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6
AR037681A1 (en) ADENOSINE A2A RECEIVING ANTAGONISTS OF 5-AMINO- [1,2,4] -BICYCLIC TRIAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, THE USE OF THE SAME, ONLY OR IN COMBINATION OF THE COMPOUNDS AND OTHER AGENTS FOR THE PREPARATION OF MEDICINES UTI THE TREATMENT OF PARKINSON'S DISEASE AND A
AR029373A1 (en) METHOD FOR THE TREATMENT OF MIGRANES, USING SELECTIVE ANTAGONIST COMPOUNDS OF THE IGLUR5 RECEPTORS, USE OF SUCH SELECTIVE ANTAGONIST COMPOUNDS IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF MIGRANES AND SAVINGS COMPOSED
EA200500882A1 (en) N-ARILSULFONIL-3-AMINOALKOXIINDOLES
AR047621A1 (en) DERIVATIVES OF N-TIAZOL-2- IL-BENZAMIDA
AR012436A1 (en) 4-AMINOPIRIDE [2,3-D] PIRIMIDINE 5,7-DISSTITUTED COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, THE USE OF THE SAME FOR LAMANUFACTURE OF MEDICINES, A PROCEDURE FOR THEIR PREPARATION.
AR046753A1 (en) BENZOXAZINE DERIVATIVES AND USES OF THE SAME
ES2090024T3 (en) CEFEMO COMPOUNDS AND PROCEDURES FOR ITS PREPARATION.
AR035312A1 (en) HYDROXAMIC ACID COMPOUNDS CONTAINING ALQUINYL AS MATRIX / TACE METALOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITION THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
FA Abandonment or withdrawal